Plant · Scientific monograph
Plantago ovata
Psyllium / Ispaghula
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Digestive health, Lipid metabolism
Research overview
Historical use
Ispaghula seed husk has established medicinal use as a bulk-forming laxative; this profile concerns husk, not unrelated Plantago species [4].
Modern research context
Psyllium husk has been studied for constipation, IBS symptoms and lipid biomarkers [1][2][3]. A 12-week IBS RCT compared psyllium, bran and placebo in 275 adults; psyllium improved relief in early months [1]. Fiber meta-analysis supports a psyllium signal but pooled all-fiber effects cannot be assigned wholly to psyllium [2]. A 28-trial lipid meta-analysis found lower LDL, with moderate certainty limited by inconsistency [3]. BMS Level B provisional for these specific outcomes pending full-text appraisal; cardiovascular event prevention is not established.
Adverse effects
Flatulence, distension and allergy, including anaphylaxis, can occur. Inadequate fluid can cause choking or esophageal/intestinal obstruction; powder inhalation may sensitize [4].
Contraindications
EMA contraindications include swallowing/throat disorders, GI narrowing, potential/existing obstruction, megacolon, undiagnosed rectal bleeding, persistent sudden bowel-habit change and failure to defecate after a laxative. Allergy is a contraindication [4]. Constipation persisting beyond three days or abdominal pain warrants medical advice; pediatric age restrictions depend on the indication [4].
Clinical and phytochemical data
Used part
Seed coats (ispaghula/psyllium husk), whole or powdered. Seed, husk and other Plantago species are not interchangeable [4].
Primary active compounds
Gel-forming mucilage polysaccharides, including arabinoxylan-type fiber; whole husk is not a purified systemic drug [4]
Mechanism of action
Water-retaining mucilage increases stool hydration/bulk; predominantly local gut action differs from systemic receptor pharmacology. Lipid-marker effects do not demonstrate prevention of cardiovascular events [3][4].
Pharmacokinetics
Absorption
Husk mucilage is minimally absorbed intact; EMA distinguishes local fiber action from uptake of degradation products [4].
Distribution
No conventional whole-husk systemic tissue-distribution profile is established; local luminal action predominates [4].
Metabolism
Limited colonic fermentation produces short-chain fatty acids; do not treat fiber as a CYP-metabolized small-molecule drug [4].
Excretion
Unabsorbed fiber and metabolites pass in feces; a conventional whole-husk elimination half-life is not applicable [4].
Safety and interactions
Drug interactions
May delay absorption of other oral medicines. EMA specifies separation and notes supervision with thyroid hormones or motility-inhibiting drugs; diabetes therapy may require review. Interaction severity depends on the medicine [4].
Toxicity
The major acute risks are mechanical obstruction and severe hypersensitivity; sufficient liquid is essential. No maximum safe dose for impaired populations is inferred from trials [4].
Special precautions
Pregnancy
EMA permits consideration when diet change fails, with limited pregnancy data; no claim of established fetal safety [4].
Lactation
EMA allows consideration when needed; specific infant-safety evidence remains limited [4].
Hepatic impairment
No hepatic dose-adjustment evidence identified for husk; impairment-specific safety is not established by these trials [4].
Renal impairment
Fluid restrictions and swallowing/obstruction risk require individual clinical assessment; no renal dose-adjustment evidence identified [4].
Sources and references
- [1] - Bijkerk CJ, de Wit NJ, Muris JW, Whorwell PJ, Knottnerus JA, Hoes AW. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ (Clinical research ed.) 2009. PMID: 19713235. DOI: 10.1136/bmj.b3154.
- [2] - van der Schoot A, Drysdale C, Whelan K, Dimidi E. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American journal of clinical nutrition 2022. PMID: 35816465. DOI: 10.1093/ajcn/nqac184.
- [3] - Jovanovski E, Yashpal S, Komishon A, Zurbau A, Blanco Mejia S, Ho HVT, Li D, Sievenpiper J, Duvnjak L, Vuksan V. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. The American journal of clinical nutrition 2018. PMID: 30239559. DOI: 10.1093/ajcn/nqy115.
- [4] - EMA/HMPC. Official herbal monograph, full regulatory text, sections 4.3–5.3. https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-plantago-ovata-forssk-seminis-tegumentum_en.pdf Accessed 2026-10-25.